First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview

Area of Science:

• Pediatric Neurology
• Neuroimmunology
• Clinical Pharmacology

Background:

• Pediatric multiple sclerosis (MS) involves disease onset before age 18.
• Established adult MS therapies, interferons (IFNs) and glatiramer acetate, are understudied in children.
• Limited pharmacokinetic data exists for these agents in pediatric populations.

Purpose of the Study:

• To review the current understanding of first-line disease-modifying therapies for pediatric MS.
• To summarize available data on the efficacy and safety of IFNs and glatiramer acetate in children.
• To identify gaps in knowledge and areas for future research in pediatric MS treatment.

Main Methods:

• Review of existing literature on immunomodulatory treatments for pediatric MS.
• Analysis of observational studies and retrospective case reports on IFNs and glatiramer acetate.
• Focus on safety profiles, adverse effects, and reported efficacy in pediatric patients.

Main Results:

• Interferon beta (IFNβ) formulations (IFNβ-1a, IFNβ-1b) and glatiramer acetate are generally safe and well-tolerated in children.
• Common adverse effects include flu-like symptoms, injection site reactions, and transient liver enzyme elevations.
• Largest cohort study (130 cases) reported reduced annual relapse rates with these agents over 4 years.

Conclusions:

• Current data suggest IFNs and glatiramer acetate are safe and effective for pediatric MS.
• Dosing recommendations are primarily based on tolerability, with many children tolerating adult doses.
• Further studies are essential to establish optimal dosing, pharmacokinetics, and comparative efficacy in pediatric MS patients.